Iconovo And Amneal Collaborate On Symbicort Rival
Planning Development Program Following Iconovo’s Pilot Study
Iconovo has brought Amneal on board as a partner to help develop a generic version of AstraZeneca’s Symbicort respiratory brand, as the Swedish inhalation specialist prepares to make major investments in the project.
You may also be interested in...
Amneal reported a 20% drop in sales in the fourth quarter of 2019, primarily due to lower turnover from its generics business. The company’s co-CEOs are trying to revitalize the company and have launched 15 new products since returning midway through last year.
A CJEU advocate general has backed a European Commission fine of almost €94m imposed on Lundbeck over “pay for delay” deals struck with four generics firms over citalopram.
Mylan and Lupin have revealed when they expect to launch their etanercept biosimilar, Nepexto, in Europe after receiving formal European Commission approval.